PMS Registry
Company Name
Protocol Number
Title of Study
Thromboembolic and Bleeding Risks of Apixaban, Rivaroxaban and Dabigatran versus Warfarin in Patients with Non-Valvular Atrial Fibrillation
Primary Objective
1. Describe clinical and demographic characteristics of OAC treatment naïve patients who were prescribed with warfarin, dabigatran, rivaroxaban or apixaban
2. Compare the safety and effectiveness for OAC treatment naïve patients prescribed dabigatran, rivaroxaban and apixaban or warfarin
Number of Sites
NA (健保資料庫回溯性研究)
Period of Study
From:2018/8/8 to:2019/8/7
Number of Patients
NA (健保資料庫回溯性研究)人
IRB Approval Date
Publication Plan / Date